Diphtheria, tetanus, pertussis, poliomyelitis, and hemophilus influenzae type b prevention.

Promotes active immunity to diphtheria, tetanus, pertussis, hemophilus influenzae type b and poliovirus (types 1, 2 and 3) by inducing production of specific antibodies and antitoxins.(UTD)

Hypersensitivity to diphtheria and tetanus toxoids, pertussis, hemophilus influenzae type b, poliovirus vaccine, or any component of the vaccine; encephalopathy occurring within 7 days of a previous pertussis vaccine (not attributable to another identifiable cause); progressive neurologic disorders (including infantile spasms, uncontrolled epilepsy, or progressive encephalopathy).(UTD)

C

Not indicated for women of childbearing age.

>10%:Central nervous system: Irritability (61% to 65%; grade 3: 3% to 4%), drowsiness (41% to 57%)Gastrointestinal: Anorexia (26% to 31%; grade 3: <1%)Local: Erythema at injection site (25% to 40%; >20 mm: 1% to 3%), pain at injection site (31% to 36%; grade 3: 2% to 3%), swelling at injection site (17% to 29%; >20 mm: 2% to 3%)Miscellaneous: Fussiness, fever

Primary immunization: Infants and Children 6 weeks to <7 years:
IM: 0.5 mL/dose; administer as a 3-dose series at 2-, 4-, and 6 months of age in 6- to 8-week intervals (preferably 8-week intervals).
Vaccination usually begins at 2 months, but may be started as early as 6 weeks of age.

There are no dosage adjustment provided in the manufacturer’s labeling.

There are no dosage adjustment provided in the manufacturer’s labeling.